Deniz Kural

Deniz Kural, Co-Founder of Totient, leads an AI-driven biotechnology company that harnesses tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient's innovative approach involves reconstructing antibodies from tissues affected by autoimmunity, infections, and cancer, collected from patients with exceptional im...